Bevacizumab-awwb (Mvasi®) is the first anti-tumor biosimilar of bevacizumab approved by FDA.388,389 Ranibizumab (Lucentis®) is a 48 kDa humanized anti-VEGF monoclonal antibody fragment, which can bind all VEGF-A isoforms, including VEGF110, VEGF121, and VEGF165 (Table 1). Here, VEGFA is linked to neoplasm.